CADTH | Evidence Driven
CADTH | Evidence Driven

everolimus

Details

Files
Generic Name:
everolimus
Project Status:
Active
Therapeutic Area:
Tuberous Sclerosis Complex (TSC)
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
SX0836-000
Call for patient/clinician input closed:
Biosimilar:
No
Fee Schedule:
Pending
Indications:
Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC).
Key Milestones2
Call for patient input open14-Dec-23
Call for patient/clinician input open14-Dec-23
Call for patient input closed12-Feb-24
Call for patient/clinician input closed12-Feb-24
Call for industry input open14-Dec-23
Call for industry input closed12-Feb-24
Submission received12-Dec-23

Files

Scope document View PDF

Related Content

Last Updated : January 15, 2024